ramipril tad 2.5 mg tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 2.5 mg - agents acting on the renin-angiotensin system
ramipril tad 5 mg tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 5 mg - agents acting on the renin-angiotensin system
ramipril tad 10 mg tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 10 mg - agents acting on the renin-angiotensin system
ramipril aristo 5 mg tablets
aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - ramipril - tablet - ramipril 5 mg - agents acting on the renin-angiotensin system
ramipril aristo 10mg tablets
aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - ramipril - tablet - ramipril 10 mg - agents acting on the renin-angiotensin system
ramipril aristo 1.25mg tablets
aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - ramipril - tablet - ramipril 1.25 mg - agents acting on the renin-angiotensin system
ramipril aristo 2.5mg tablets
aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - ramipril - tablet - ramipril 2.5 mg - agents acting on the renin-angiotensin system
ramipril teva 10 mg
teva pharmaceutical industries ltd, israel - ramipril - tablets - ramipril 10 mg - ramipril - ramipril - hypertension . congestive heart failure . reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.
ramipril teva 5 mg
teva pharmaceutical industries ltd, israel - ramipril - tablets - ramipril 5 mg - ramipril - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.
ramipril teva 5 mg
teva pharmaceutical industries ltd, israel - ramipril - tablets - ramipril 5 mg - ramipril - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.